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SCS was markedly greater in the SCS group, with a mean EQ-5D
score difference of 0,26 (95% CI: 0,14–0,39) and 0,21 (95% CI:
0,08–0,34), respectively at 3- and 6-months. CONCLUSIONS:
SCS added to CMM in patients with neuropathic leg and back
pain results in higher costs to Spanish National Health System,
but also generates important improvements in patients’ EQ-5D
in 6-months period. Over time, savings in drug costs might









MANAGEMENT OF HERPES ZOSTER (HZ) AND
POST-HERPETIC NEURALGIA (PHN) IN BELGIUM:
A COST OF ILLNESS STUDY
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1IMS Health, Brussels, Belgium, 2Sanoﬁ Pasteur MSD, Brussels, Belgium
OBJECTIVES: To describe the current Belgian management
and resource use associated with HZ and PHN in patients aged
greaer or equal to 50 years in order to estimate the associated
cost (societal perspective) in this population. METHODS:
Three parallel Expert Surveys were performed: 1 focussed on
acute phase (HZ, ﬁrst month, diagnosis before and after 72
hours after appearance of rash) in a sample of dermatologists/
ophthalmologist (N = 7), 1 focussed on chronic phase (PHN, 1
and 3-month deﬁnition: pain occurring or persisting at least 1
month/3 months after rash onset) in a sample of neurologists/
pain-specialists (N = 8), and 1 combined both phases (GPs,
N = 4). Management was described in terms of pain severity
(no, mild, moderate and severe pain). Questions were related to
current medical practice (medication, non-pharmacological
treatment, tests, consultations, hospitalisation and work absen-
teeism). Costs were calculated by multiplying average resource
use obtained from the Expert Survey with speciﬁc unit costs
(ofﬁcial tariffs). RESULTS: Total cost of management of HZ
ranged between €100 (no pain) and €975 (severe pain) if diag-
nosis of HZ was made within 72 hours after appearance of
rash. If diagnosis was made after 72 hours after appearance of
rash, ﬁgures were somewhat lower (between €68 and €872 for
no and severe pain respectively). In all pain categories, impor-
tant cost drivers were costs for oral medication and consulta-
tions. In severe pain patients, most important cost factors were
costs related to hospitalization (€310) and work absenteeism
(€263). For PHN, 1-month deﬁnition, total management’s cost
ranged between €133 (mild pain) and €920 (severe pain). For
PHN, 3-month deﬁnition, this cost was higher and ranged
between €279 (mild pain) and €1727 (severe pain). Important
cost drivers were comparable to those in HZ. CONCLU-
SIONS: HZ and PHN cause an economic burden. Management
cost can rise to €975 for severe pain in HZ, and to €1727 in
PHN.
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OBJECTIVES: To systematically review the cost of illness and
utility literature relating to systemic lupus erythematosus (SLE),
and in so doing to identify and elucidate the major cost-drivers
in the cost of illness of SLE. METHODS: The bibliographic
databases: Medline, Embase, and NHSEED were searched on
the 14th of May 2007. Health economic studies reporting data
on resource-utilisation, costs and utility relating to the syndrome
were included after an initial review of the abstracts of retrieved
citations and a further review of the full-text publications.
Furthermore, bibliographies of included studies were interro-
gated for additional citations. Data were extracted into pre-
deﬁned data extraction grids and were analysed using Microsoft
Excel™. RESULTS: The search of the bibliographic databases
retrieved 1182 citations. Of these, a total of 19 studies reporting
cost of illness and/or utility data were included in the review.
Only two studies reported both indirect and total costs, with
indirect costs contributing 50.24% and 66.97% of the overall
total costs of SLE. In these two studies the annual mean direct
per patient cost of SLE amounted to CAN$7382 and £2613 in
respective Canadian and UK populations. Of the direct costs,
across all included studies reporting these data, hospitalisation
was the most important cost-driver contributing between 24.6%
and 56.1% of the direct costs of SLE. The systematic review also
identiﬁed an absence of robust utility data, with the visual ana-
logue scale (VAS) being the main mechanism for deriving these
data. CONCLUSIONS: This review has highlighted the signiﬁ-
cant health economic impact of the disease, in terms of direct
costs and productivity losses and the need for more robust utility
data. Recent recommendations have deﬁned a core set of out-
comes to be included in any SLE trial programme; and from a
health economic perspective these include direct and indirect
costs, health-related quality of life and utilities. This review rein-
forces these recommendations and has identiﬁed hospitalisations
and productivity losses as key cost drivers in the cost of illness
of SLE.
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